About

About Avalyn Pharma Avalyn is reimagining the future of pulmonary fibrosis treatment with a pipeline of new inhaled formulations of approved medicines designed to reduce systemic exposure and deliver medication directly to the site of disease. Pulmonary fibrosis is characterized by scarring of lung tissue, decline in lung function, and reduced exercise capacity and quality of life, and is associated with increased mortality. Currently approved therapeutic options slow pulmonary fibrosis progression but are associated with significant toxicities that restrict their use and dosing. Avalyn’s inhaled approach is designed to tackle the underlying pathophysiology of pulmonary fibrosis at its source and reduce systemic exposure and deliver medication directly to the site of disease. AP01, an optimized inhaled formulation of pirfenidone administered via nebulization, is currently being studied in the ongoing MIST Phase 2b study in progressive pulmonary fibrosis (PPF). AP01 has been assessed in over 150 individuals with different forms of pulmonary fibrosis and demonstrated clinical proof-of-concept with promising signals of efficacy and safety, supporting continued clinical development. The company completed two Phase 1 studies for AP02, inhaled nintedanib administered via nebulization, and is currently running a Phase 2 AURA study in patients with idiopathic pulmonary fibrosis (IPF). For more information, please visit avalynpharma.com and follow us on LinkedIn.